Campaigners in the UK have warned that the delay in introducing a new vaccine against meningitis will cost lives, The Telegraph reported Thursday.
In January 2013, Meningitis B vaccine, Bexsero, was licensed by the EU and the UK Joint Committe on Vaccination and Immunisation approved the vaccine for NHS use in March if it could be obtained at a suitable price.
Andy Hopkinson, of charity, Meningitis Now (UK), said that "we hope negotiations between the UK Department of Health and the vaccine company will be concluded swiftly."
Division head of Novartis Vaccines, Andrin Oswald, asked the government to act swiftly to "avoid further loss of lives and patient suffering."
He added that "we are willing to work with the UK government on the next steps and are waiting for the public procurement process to start."